Ranbaxy Laboratories Ltd said on Thursday that it has bagged the US Food and Drug Administration's approval for manufacturing and marketing Loratadine and Pseudoephedrine Sulfate Extended-release tablets.
The extended-release tablets, 10mg/240 mg, were found bio-equivalent to Schering Corporation's listed drug Claritin whose total sales was $64.5 million in the OTC market in July 2004, a Ranbaxy release said in New Delhi.
The drug, to be introduced in the market by October-end 2004, is for temporary relief in hay fever and other upper respiratory allergies, nasal congestion, it added.
Ranbaxy vice president (sales and marketing) Sandeep Parekh said, "Ohm laboratories will market the product in the private label or store brand segment of the US healthcare system."
Ohm is the wholly-owned subsidiary of Ranbaxy engaged in the sale and distribution of generic and branded private labels, OTC products in the US healthcare system, it added.
